North Korea has developed a vaccine candidate against COVID-19

North Korea has developed a vaccine candidate against COVID-19, reported on a North Korean website about the scientific achievements of the "Mire" ("Future").

According to the portal, scientists at the research center of the Institute of medicine studies of medicine and biology has developed recombinant subunit vaccine based on genetic sequence, thorn S-protein from the membrane of the coronavirus that is associated with the angiotensin converting enzyme 2 (ACE2) human in the membranes of our cells, thus attaching it to the cage.

The safety and efficacy of the vaccine has been proven on animals, and since the beginning of July, began its clinical trials. "Given that the DPRK no sick with coronavirus, is now being discussed how to conduct the third phase clinical trials," the portal says.

Subunit vaccines consist of one or more purified immunogenic surface proteins of the virus and contain its living components, and therefore are considered safe. They aimed only to induce an immune response in the body. Recombinant subunit vaccines on the same principle, but using the methods of genetic engineering. Genetic material of the virus is inserted into other cells, for example yeast or insect cells, which then produce the desired antigen. After that, the antigen is isolated, purify and prepare the vaccine.

The disadvantage of simple subunit vaccines and recombinant subunit vaccines is their low immunogenicity and, therefore, the need for regular vaccination.

Recent data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.